BioNTech SE is navigating a critical transition, leveraging a massive €17 billion war chest to fund an ambitious pivot from pandemic windfalls to a sustainable oncology business. The company’s stock, trading around €87.00, reflects a cautious optimism as investors weigh promising clinical data against a challenging financial outlook marked by expected revenue declines.
The most compelling recent data comes from the antibody-drug conjugate trastuzumab pamirtecan (BNT323). At the Society of Gynecologic Oncology annual meeting, BioNTech presented Phase 2 results showing a confirmed objective response rate of 47.9% in patients with advanced, recurrent endometrial cancer expressing HER2. Efficacy was particularly strong in patients with the highest HER2 expression (IHC 3+), where the response rate exceeded 70%, with a median progression-free survival of 8.1 months. Crucially, the candidate also showed activity in lower expression cohorts, with response rates of 33.9% for IHC 1+ and 40.4% for IHC 2+, potentially addressing an unmet need where approved therapies like Enhertu are restricted to the highest expressors. The safety profile was deemed manageable, with grade 3 or higher treatment-related adverse events occurring in 46.9% of patients.
This data has solidified plans for a Biologics License Application (BLA) with the FDA in 2026, a filing that carries Fast-Track and Breakthrough Therapy designations. It represents the first major commercial test of BioNTech’s oncology transformation, with revenue from this pipeline not expected before 2027.
Simultaneously, the company is advancing a significant three-way collaboration with Boehringer Ingelheim and Bristol Myers Squibb. The partners are preparing a combination therapy trial for advanced small cell lung cancer, targeting one of the most aggressive cancer forms. The study will combine Obrixtamig, a DLL3-targeting T-cell engager, with Pumitamig, a bispecific antibody against PD-L1 and VEGF-A. Early Phase 2 data for Pumitamig alone has been notable, showing a 100% disease control rate and a 76.3% objective response rate. Patient recruitment for the combination study is slated to begin in the second half of 2026.
Should investors sell immediately? Or is it worth buying BioNTech?
This alliance supports BioNTech’s overarching goal of having 15 active Phase 3 oncology studies by the end of 2026, a stark shift from its previous identity as a single-product company. The financial runway to attempt this is secure, with liquidity reserves reported between €17 and €17.2 billion. This cushion is essential as the company forecasts a roughly 25% revenue drop to €2.0-2.3 billion for 2026, following a net loss of €1.14 billion in the prior year.
Analyst sentiment reflects a spectrum of views on this high-stakes strategy. The average price target stands at $133. BofA Securities raised its target to $130 with a Buy rating, while Morgan Stanley adjusted its target up to $126. Berenberg remains the most bullish, maintaining a $155 target and Buy recommendation. Among 18 analysts, 13 recommend buying the stock. A more cautious stance comes from Leerink Partners, which rates BioNTech at Market Perform with a $94 target, citing diminished prospects for its CTLA-4 candidate, Gotistobart, in a Phase 3 lung cancer study.
Technically, the share price movement has been positive, with a weekly gain of approximately 9.6% to €87.00, placing it just below its 200-day moving average of €87.98. The stock remains about 20% below its 52-week high of €105.90. The coming months will be defined by execution, as BioNTech works to hit its dual 2026 milestones: the pivotal BLA submission for BNT323 and the initiation of its landmark lung cancer combination trial.
Ad
BioNTech Stock: Buy or Sell?! New BioNTech Analysis from April 18 delivers the answer:
The latest BioNTech figures speak for themselves: Urgent action needed for BioNTech investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from April 18.
BioNTech: Buy or sell? Read more here...
